Management of Oligoprogressive Castration Resistant Prostate Cancer (PCS X)

This study is investigating the best treatment approach for men with prostate cancer that has stopped responding to hormone therapy (called castration-resistant prostate cancer, or CRPC) and is showing limited progression in a small number of spots. Researchers want to know if targeting those few progressing areas with radiation can delay the cancer from spreading further. **You may be eligible if...** - You have been diagnosed with castration-resistant prostate cancer (prostate cancer that keeps growing despite hormone-lowering treatment) - Your testosterone levels are very low (at or below 50 ng/dL) - Your PSA levels have risen on at least two consecutive measurements - Your cancer has not spread visibly to organs on standard scans - Your PSA doubling time is 10 months or less **You may NOT be eligible if...** - Your cancer has spread widely to multiple areas - You do not meet the specific PSA progression or testosterone criteria - Your cancer has grown beyond what targeted radiation could address Talk to your doctor to see if this trial is right for you.